Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Authors :: Russell-Jones, David
Cuddihy, Robert M
Hanefeld, Markolf
Kumar, Ajay
González, Jose G
Chan, Melanie
Wolka, Anne M
Boardman, Marilyn K
DURATION-4 Study Group
Mathieu, Chantal
Publication Year :: 2012
Publisher :: American Diabetes Association, 2012.
Abstract: To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes. ispartof: Diabetes Care vol:35 issue:2 pages:252-258 ispartof: location:United States status: published

Subjects :: Endocrinology & Metabolism
MELLITUS
Science & Technology
PARALLEL-GROUP
VILDAGLIPTIN
INSULIN SENSITIVITY
GLYCEMIC CONTROL
TOLERABILITY
INITIAL COMBINATION THERAPY
OPEN-LABEL
Life Sciences & Biomedicine
GLICLAZIDE

Tools